|
π
|
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
11 auth.
Ashley Ghiaseddin,
D. Reardon,
W. Massey,
Alexandra Mannerino,
E. Lipp,
J. Herndon,
...
F. McSherry,
A. Desjardins,
D. Randazzo,
H. Friedman,
K. Peters
|
5 |
2017 |
5
π
|
|
π
|
Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
12 auth.
Ashley Ghiaseddin,
D. Reardon,
W. Massey,
Alexandra Mannerino,
E. Lipp,
J. Herndon,
...
F. McSherry,
A. Desjardins,
D. Randazzo,
G. VlahoviΔ,
H. Friedman,
K. Peters
|
2 |
2015 |
2
π
|
|
π
|
Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).
19 auth.
M. Affronti,
A. Desjardins,
H. Friedman,
K. Peters,
J. Herndon,
F. McSherry,
E. Lipp,
A. Brickhouse,
W. Massey,
Elizabeth S. Miller,
...
S. Cheshire,
Christina K. Cone,
K. Kalinowski,
Jung-Young Kim,
H. H. Lay,
V. Poillucci,
C. Southerland,
J. Tetterton,
J. Vredenburgh
|
2 |
2012 |
2
π
|
|
π
|
Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.
11 auth.
K. Peters,
J. Vredenburgh,
A. Desjardins,
H. Friedman,
J. Herndon,
A. Coan,
...
F. McSherry,
E. Lipp,
A. Brickhouse,
W. Massey,
D. Reardon
|
1 |
2012 |
1
π
|
|
π
|
QOLP-18. A TIME-BASED MODEL OF EARLY PALLIATIVE CARE INTERVENTION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA, A SINGLE INSTITUTION FEASIBILITY STUDY
13 auth.
Margaret O Johnson,
L. Ramirez,
J. Herndon,
W. Massey,
E. Lipp,
M. Affronti,
Jung-Young Kim,
H. Friedman,
A. Desjardins,
D. Randazzo,
...
D. Ashley,
D. Casarett,
K. Peters
|
1 |
2019 |
1
π
|
|
π
|
ACTR-64. PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
11 auth.
A. Desjardins,
D. Randazzo,
K. Peters,
Margaret O Johnson,
W. Massey,
J. Herndon,
...
F. McSherry,
E. Lipp,
P. Nadler,
I. Horak,
H. Friedman
|
1 |
2017 |
1
π
|
